OCT 09, 2019 7:30 AM PDT

Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia

Speaker

Abstract

Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading causes of childhood cancer mortality. This is largely due to specific leukemia subtypes being resistant to treatment. One of these subtypes is hypodiploid B cell leukemia characterized by multiple chromosomal losses. For these patients, treatment options remain limited, and their prognosis is dim.

Learning Objectives:

1. How to integrate genomics and proteomics profiling with drug screens to identify potential therapeutic targets

2. How to move from in vitro to in vivo preclinical studies to inform new clinical trials.

3. The audience will learn about hypodiploidy: from cytogenetics to prognosis to drug response in the context of leukemia.

 


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
MAR 02, 2022 9:00 AM PST
C.E. CREDITS
MAR 02, 2022 9:00 AM PST
Date: March 02, 2022 Time: 9:00am (PST), 12:00pm (EST) Single cell RNA-seq is known to only capture a small fraction of the transcriptome of each cell. Often, this is due to inherent limitat...
NOV 30, 2021 11:00 AM PST
C.E. CREDITS
NOV 30, 2021 11:00 AM PST
Date: November 30, 2021 Time: 11:00am (PDT), 2:00pm (EDT) In the recent years, measurable residual disease (MRD) assessment on multiple myeloma patients has gained increasing relevance. After...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
OCT 09, 2019 7:30 AM PDT

Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia



Show Resources
Loading Comments...
Show Resources